CONTROLLED RANDOMIZED PILOT STUDY TO COMPARE THE EFFICACY OF DIFFERENT IRON FORMULATIONS: SUCROSOMAL FERRIC PYROPHOSPHATE, SUNACTIVE Fe AND INTRAVENOUS FERRIC GLUCONATE
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 148
- 主要终点
- HB
研究概览
简要总结
The purpose of the study is to evaluate the effects of martial therapy, comparing different formulations, sucrosomal ferric pyrophosphate, SunActive®Fe micronized and ferric gluconate and different ways of administration, orally and intravenous, in subjects affected by sideropenic microcytic hypochromic anemia identified by the simultaneous presence of anemia, microcytosis and hypoferremia.
详细描述
Background: Iron deficiency anemia (IDA) still remains universally a worldwide problematics. Anemia is defined as a hemoglobin value <12.0 g/dL (7.45 mmol/L). Management of IDA is based on martial iron supplementation. The purpose of the study is to evaluate the effects of martial therapy, comparing different formulations, sucrosomal ferric pyrophosphate, SunActive®Fe micronized and ferric gluconate and different ways of administration, orally and intravenous, in subjects affected by sideropenic microcytic hypochromic anemia identified by the simultaneous presence of anemia, microcytosis and hypoferremia.
Trial Design, Methods and Findings: Clinical data from 106 outpatients (82.8% female and 17.2% male, mean age 50.4 years) were collected at Department of Internal Medicine, National Relevance and High Specialization Hospital Trust, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy. The study envisaged five arms (2 + 3). At the first two arms were assigned patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized or Lipofer®. At the other three arms were assigned patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized, Lipofer® or with intravenous ferric gluconate infusions according to departmental protocols. The followed methodology is defined in the PROBE project (acronym of Prospective Randomized Open Blinded End-point). The end points will be blinded with respect to the three treatments, as it will be the statistical analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of iron deficiency anemia, microcytic and hypochromic
排除标准
- •Diagnosis of Celiac Disease
- •Patients who refuse to sign the informed consent
- •Clinically relevant cognitive Turbe
- •Hemodynamic instability defined by the presence of low blood pressure SBP <100 FC> 100
- •Dyspnea after modest effort worsening over the past 10 days
- •Oxygen peripheral saturation values <94%
- •Ischemic heart Recent and / or lower limbs
- •Acute conditions with subacute or at recruitment
研究组 & 干预措施
Patients with non-severe anemia treated with SunActive®Fe
Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized
干预措施: SunActive®Fe (Dietary Supplement)
Patients with non-severe anemia treated with Lipofer®
Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®
干预措施: Lipofer® (Dietary Supplement)
Patients with severe anemia with Lipofer®
Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®
干预措施: Lipofer® (Dietary Supplement)
Patients with severe anemia with SunActive®Fe
Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized
干预措施: SunActive®Fe (Dietary Supplement)
Patients with severe anemia with intravenous ferric gluconate
Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
干预措施: Intravenous ferric gluconate (Dietary Supplement)
结局指标
主要结局
HB
时间窗: Three months
Mean change of hemoglobin concentration at three months
次要结局
未报告次要终点
研究者
Salvatore Corrao, MD
Professor
University of Palermo
